Expression of CD44+/CD24-, RAD6 and DDB2 on chemotherapy response in ovarian Cancer: A prospective flow cytometry study

Sihombing, Unedo Hence Markus; Andrijono,; Purwoto, Gatot; Gandamihardja, Supriadi; Harahap, Alida; Rustamadji, Primariadewi; Kekalih, Aria; Widyawati, Retno; Fuady, Dzicky Rifqi

doi:10.1016/j.gore.2022.101005

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[29][30][31][32] According to RECIST, the therapy's response is classified as a complete response, partial response, stable disease or progressive disease, then classified into chemoresistant or chemosensitive groups. [33][34][35] The patients were chemosensitivity if there is the loss of all tumour masses or pathological lymph nodes (complete response), and if there is a tumour that becomes at least 30% smaller than the longest diameter of the tumour (partial response).…”

Section: Study Populationmentioning

confidence: 99%

Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1‐pRB‐E2F1 pathway

Wang

Zhang

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

Section: Study Populationmentioning

confidence: 99%

Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1‐pRB‐E2F1 pathway

Wang

Zhang

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The clinical significance and prognostic value of CD44 as a CSC surface marker in patients with ovarian cancer remain controversial. CSCs expressing CD44 were demonstrated to be resistant to chemotherapy and associated with poor survival in ovarian cancer in many studies [ 164 , 165 , 166 ]. Of 96 patients with stage IIIB-IVA primary serous epithelial ovarian cancer, 49% showed variable CD44 expression [ 156 ].…”

Section: Ovarian Cancer Stem Cells Markersmentioning

confidence: 99%

The Role of Cancer Stem Cell Markers in Ovarian Cancer

Frąszczak,

Barczyński

2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynaecological cancer and the eighth most common female cancer. The early diagnosis of ovarian cancer remains a clinical problem despite the significant development of technology. Nearly 70% of patients with ovarian cancer are diagnosed with stages III–IV metastatic disease. Reliable diagnostic and prognostic biomarkers are currently lacking. Ovarian cancer recurrence and resistance to chemotherapy pose vital problems and translate into poor outcomes. Cancer stem cells appear to be responsible for tumour recurrence resulting from chemotherapeutic resistance. These cells are also crucial for tumour initiation due to the ability to self-renew, differentiate, avoid immune destruction, and promote inflammation and angiogenesis. Studies have confirmed an association between CSC occurrence and resistance to chemotherapy, subsequent metastases, and cancer relapses. Therefore, the elimination of CSCs appears important for overcoming drug resistance and improving prognoses. This review focuses on the expression of selected ovarian CSC markers, including CD133, CD44, CD24, CD117, and aldehyde dehydrogenase 1, which show potential prognostic significance. Some markers expressed on the surface of CSCs correlate with clinical features and can be used for the diagnosis and prognosis of ovarian cancer. However, due to the heterogeneity and plasticity of CSCs, the determination of specific CSC phenotypes is difficult.

show abstract

“…One of them, collagen type XI alpha 1 chain (COL11A1), was found to be a biomarker of chemoresistance and correlated with worse survival [51]. The flow cytometric analysis of the blood of ovarian cancer patients found significant relationship between chemoresistance and both increased the number of CD44+/CD24− stem cells and over-expression of ubiquitinconjugating enzyme E2 coding gene RAD6 [52]. The population of CD44+/CD117+ stem cells were related to platinum and paclitaxel resistance [53].…”

Section: Genetic and Proteomic Biomarkersmentioning

confidence: 99%

Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer

Wilczyński,

Paradowska,

Wilczyńska

et al. 2023

Current Oncology

View full text Add to dashboard Cite

High-grade serous ovarian cancer (HGSOC) is one of the most lethal tumors generally and the most fatal cancer of the female genital tract. The approved standard therapy consists of surgical cytoreduction and platinum/taxane-based chemotherapy, and of targeted therapy in selected patients. The main therapeutic problem is chemoresistance of recurrent and metastatic HGSOC tumors which results in low survival in the group of FIGO III/IV. Therefore, the prediction and monitoring of chemoresistance seems to be of utmost importance for the improvement of HGSOC management. This type of cancer has genetic heterogeneity with several subtypes being characterized by diverse gene signatures and disturbed peculiar epigenetic regulation. HGSOC develops and metastasizes preferentially in the specific intraperitoneal environment composed mainly of fibroblasts, adipocytes, and immune cells. Different HGSOC subtypes could be sensitive to distinct sets of drugs. Moreover, primary, metastatic, and recurrent tumors are characterized by an individual biology, and thus diverse drug responsibility. Without a precise identification of the tumor and its microenvironment, effective treatment seems to be elusive. This paper reviews tumor-derived genomic, mutational, cellular, and epigenetic biomarkers of HGSOC drug resistance, as well as tumor microenvironment-derived biomarkers of chemoresistance, and discusses their possible use in the novel complex approach to ovarian cancer therapy and monitoring.

show abstract

Expression of CD44+/CD24-, RAD6 and DDB2 on chemotherapy response in ovarian Cancer: A prospective flow cytometry study

Cited by 3 publications

References 36 publications

Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1‐pRB‐E2F1 pathway

Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1‐pRB‐E2F1 pathway

The Role of Cancer Stem Cell Markers in Ovarian Cancer

Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer

Contact Info

Product

Resources

About